SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc.

SAB Bio develops disease-modifying therapies for people impacted by type 1 diabetes.

SAB Bio

A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D)

National Institutes of Health

U.S. Department of Defense

JDRF T1D Fund

BVF Partners

Commodore Capital

Marshall Wace

RA Capital Management

RTW Investments

Sessa Capital

T. Denny Sanford

South Dakota Equity Partners

Merck

Sioux Falls Development Foundation

SAB BIO

We are excited to announce we have evolved our name and visual identity! 

This is an important milestone, reflecting our strategic evolution and focus on addressing serious unmet needs in #type1diabetes. We look forward to showcasing our new branding during our poster presentation at the American Diabetes Association  84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida and hope to see you there!

Read more about this announcement and check out our website at sab.bio.

#t1d #type1diabetes #diabetes #ADASciSessions

We are pleased to welcome @Lucy To as our newly appointed CFO, effective August 12. 

Lucy joins SAB with more than 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company.

Read more about her joining SAB in the release found here: https://lnkd.in/dkHPUyH2

SAB was featured in the latest publication of Refresh Miami - link below!

What an incredible week we've had attending American Diabetes Association #adascisessions and meeting reknowned #type1diabetes advocates, researchers and thought leaders. 

Attending SAB BIO representatives included our Chairman and CEO Samuel Reich, our Co-Founder and President Eddie J Sullivan, EVP and COO Christoph Bausch, VP of Clinical Operations Angela Parizek, VP of Clinical Development Stan Stoyanov MD, MBA, and Senior Program Manager Eric Sandhurst, PhD. 

We look forward to continuing to build relationships with the other attendees we met. See you next year!

We are pleased to note our upcoming poster presentation at this week's American Diabetes Association #scientificsessions in Orlando on Sunday, June 23 for #ADA2024. 

Details about where to find our poster and connect with the presenter can be found below. 

https://lnkd.in/eX58xMxh

We've met so many incredible #type1diabetes advocates during the American Diabetes Association #ADAscisessions, and today SAB Senior Program Manager Eric Sandhurst, PhD presented in the Poster Hall and took questions. Also pictured below is our COO & EVP, Christoph Bausch. 

We'll be here one more day in the Poster Hall at 885-P if you'd like to check out our presentation. Come say hello!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-8.99M -	20.12M 323.87%	-17.14M 185.22%	-17.14M 0%	-42.19M 146.11%
depreciation and amortization	323.41K -	548.18K 69.50%	1.65M 201.65%	1.65M 0%	3.75M 126.49%
deferred income tax	421 -	-2.25K 634.92%			-2.85M -
stock based compensation	371.39K -	1.30M 248.81%	2.31M 78.68%	2.31M 0%	2.42M 4.71%
change in working capital	-923.37K -	-11.95M 1,194.64%	13.45M 212.55%	13.45M 0%	2.33M 82.71%
accounts receivables	-2.56M -	-17.75M 592.60%	12.56M 170.75%	12.56M 0%	5.56M 55.76%
inventory		484.84K -
accounts payables	1.56M -	5.21M 235.14%	-2.94M 156.33%	-2.94M 0%	-2.70M 7.96%
other working capital	84.50K -	100K 18.35%	3.83M 3,731.58%	3.83M 0%	-528.64K 113.80%
other non cash items	1 -	-2 300%	3.48M 173,999,300%	3.48M 0%	11.43M 228.57%
net cash provided by operating activities	-9.21M -	10.00M 208.58%	3.76M 62.43%	3.76M 0%	-25.12M 768.32%
investments in property plant and equipment	-608.75K -	-12.73M 1,991.46%	-10.94M 14.04%	-10.94M 0%	-197.15K 98.20%
acquisitions net		9K -		76.39K -	44.45K 41.81%
purchases of investments
sales maturities of investments
other investing activites				-76.39K -
net cash used for investing activites	-608.75K -	-12.72M 1,989.98%	-10.94M 13.98%	-10.94M 0%	-152.70K 98.60%
debt repayment	-623.27K -	-1.58M 153.42%	-227.27K 85.61%	-227.27K 0%	-390.44K 71.80%
common stock issued		9.90M -	6.75K 99.93%	76.97K 1,040.31%	67.16M 87,158.29%
common stock repurchased				-5.52M -
dividends paid
other financing activites	4.30M -	661.61K 84.63%	34.34M 5,090.39%	39.79M 15.87%	59.40M 49.28%
net cash used provided by financing activities	3.68M -	8.98M 143.98%	34.12M 279.85%	34.12M 0%	66.77M 95.70%
effect of forex changes on cash					18.14K -
net change in cash	-6.14M -	6.26M 202.00%	26.93M 329.96%	26.93M 0%	41.52M 54.15%
cash at beginning of period	12.49M -	6.35M 49.18%	12.61M 98.71%	12.61M 0%	15.05M 19.32%
cash at end of period	6.35M -	12.61M 98.71%	39.55M 213.59%	39.55M 0%	56.57M 43.04%
operating cash flow	-9.21M -	10.00M 208.58%	3.76M 62.43%	3.76M 0%	-25.12M 768.32%
capital expenditure	-608.75K -	-12.73M 1,991.46%	-10.94M 14.04%	-10.94M 0%	-197.15K 98.20%
free cash flow	-9.82M -	-2.73M 72.24%	-7.19M 163.49%	-7.19M 0%	-25.32M 252.35%

BIO:SAB

SAB Bio

Last Close

4.13

05/11 21:00

Market Cap

29.53M

Beta: -

Volume Today

60.47K

Avg: -

Preview